SIETES :: 92261 citas

Resultados de la búsqueda por HIPNOSEDANTES REFINAR BÚSQUEDA

1.

2.

Johansen ME. Gabapentinoid use in the United States 2002 through 2015. JAMA Intern Med 2018:2 de enero. [Ref.ID 102440]

3.

Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol 2017;84:1. [Ref.ID 102184]

4.

Laatikainen O, Mietttunen J, Sneck S, Lehtiniemi H, Tenhunen O, Turpeinen M. The prevalence of medication-related adverse events in inpatients-a systematic review and meta-analysis. Eur J Clin Pharmacol 2017;73:1539-49. [Ref.ID 102145]

5.

Brett J, Daniels B, Karanges EA, Buckley NA, Schneider C, Nassir A, McLachlan AJ, Pearson S-A. Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study. Br J Clin Pharmacol 2017;83:2581-8. [Ref.ID 102118]

6.

Pinto RZ, Verwoerd AJH, Koes BW. Which pain medications are effective for sciatica (radicular leg pain)?. BMJ 2017;359:j4248. [Ref.ID 102095]

7.

Patel P, Leeder JS, Piquette-Miller M, Dupuis LL. Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol 2017;83:2148-62. [Ref.ID 102081]

8.

9.

Herr M, Sirven N, Grondin H, Pichetti S, Sermet C. Frailty, polypharmacy, and potentially inappropriate medications in old people: findings in a representative sample of the French population. Eur J Clin Pharmacol 2017;73:1165-72. [Ref.ID 102024]

10.

Morgan SG, Weymann D. Patterns, predictors and persistence of chronic sedative use: a population-based observational study of older adults in British Columbia, Canada. Eur J Clin Pharmacol 2017;73:1001-8. [Ref.ID 101998]

11.

Ramaekers JG. Drugs and driving research in medicinal drug development. Trends Pharmacol Sci 2017;38:319-21. [Ref.ID 101986]

12.

Waade RB, Molden E, Martinsen MI, Hermann M, Ranhoff AH. Psychotropics and weak opioid analgesics in plasma samples of older hip fracture patients – Detection frequencies and consistency with drug records. Br J Clin Pharmacol 2017;83:1397-404. [Ref.ID 101985]

13.

Bénard-Laribière A, Noize P, Pambrun E, Bazin F, Verdoux H, Tournier M, Bégaud B, Pariente A. Trends in incident use of benzodiazepines and Z-drugs in France from 2006 to 2012: a population-based study. Pharmacoepidemiol Drug Saf 2017;26:162-9. [Ref.ID 101951]

14.

Bushnell G, Stürmer T, Gaynes BN, Pate V, Miller M. Simultaneous antidepressant and benzodiazepine new use and subsequent Long-term benzodiazepine use in adults with depression, United States, 2001-2014. JAMA Psychiatry 2017;74:747-55. [Ref.ID 101937]

15.

Née M, Avalos M, Luxcey A, Contrand B, Salmi L-R, Fourrier-Réglat A, Gadegbeku B, Lagarde E, Orriols L. Prescription medicine use by pedestrians and the risk of injurious road traffic crashes: A case-crossover study. PLOS Medicine 2017;14:18 de julio. [Ref.ID 101913]

16.

Patorno E, Glynn RJ, Levin R, Lee MP, Huybrechts KF. Benzodiazepines and risk of all cause mortality in adults: cohort study. BMJ 2017;358:j2941. [Ref.ID 101907]

17.

Anónimo. FDA announces list of off-patent drugs with no competition. DIA Daily 2017:1. [Ref.ID 101658]

18.

Poudel DR, Acharya P, Ghimire S, Dhital R, Bharati R. Burden of hospitalizations related to adverse drug events in the USA: a retrospective analysis from large inpatient database. Pharmacoepidemiol Drug Saf 2017;26:635-41. [Ref.ID 101626]

19.

Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]

20.

Larkin I, Ang D, Steinhart J, Chao M, Patterson M, Sah S, Wu T, Schoen-baum M, Hutchins D, Brennan T, Loewen-stein G. Association between academic medical center pharmaceutical detailing policies and physician prescribing. JAMA 2017;317:1785-95. [Ref.ID 101559]